InflaRx (IFRX) faces sell risks with weak revenue prospects, failed drug expansion, and dwindling cash. Read here for an ...
The FDA's fast track designation aims to expedite ITM-94's development for diagnosing clear cell renal cell carcinoma. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback